Hypertrophic obstructive cardiomyopathy
Conditions
Interventions
HOCM group:None
Mitral stenosis group:None
Sponsors
Second Xiangya Hospital of CSU
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.HOCM group: Met the HOCM diagnostic criteria of international guidelines (such as ESC or ACC/AHA) (echocardiography shows left ventricular wall thickness >=15 mm, or >=13 mm with family history, accompanied by left ventricular outflow tract obstruction); 2.HOCM group: Age >=18 years old; 3.HOCM group: Underwent myocardial resection or heart transplantation, and myocardial tissue samples could be obtained during the operation; 4.HOCM group: Patients signed the informed consent form; 5.Mitral stenosis group: Clinical diagnosis: Confirmed as mitral stenosis (MS) by echocardiography, requiring surgical intervention (such as mitral valve replacement); 6.Mitral stenosis group: Feasibility of intraoperative samples: Residual myocardial tissue attached to the chordae tendineae can be obtained during the operation, which is greater than or equal to 50mg; 7.Mitral stenosis group: Age and gender matched with the experimental group (e.g. ±5 years old); 8.Mitral stenosis group: Patients sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Both the experimental group and the control group excluded those with other severe heart diseases (such as acute myocardial infarction, dilated cardiomyopathy, active myocarditis, etc.). 2.Both the experimental group and the control group excluded those who had previously received cardiac radiotherapy or chemotherapy; 3.Both the experimental group and the control group excluded the possibility that systemic diseases (such as end-stage renal disease, active tumors, and autoimmune diseases) might affect myocardial tissue analysis; 4.Both the experimental group and the control group excluded active infections (such as endocarditis, active phases of HIV, HBV, and HCV). 5.Both the experimental group and the control group excluded pregnant or lactating women; 6.Both the experimental group and the control group excluded: samples of substandard quality (such as insufficient intraoperative sampling, severe tissue necrosis or improper fixation); 7.Specific exclusion in the experimental group: Only hypertrophic obstructive cardiomyopathy (HOCM) was allowed, and patients with non-obstructive HCM were excluded; 8.The experimental group specifically excluded: if amyloidosis, Fabry disease and other infiltrative cardiomyopathies coexist;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BMP4?BMPR1A?BMPR1B?BMPR2; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory factors such as IL-1 ß, TNF- a, and IL-6;SMAD1/5/8; | — |
Countries
China
Contacts
Public ContactJunmei Xu
Second Xiangya Hospital of CSU
Outcome results
None listed